Get started
Author

Antonina V. Artemeva

Observed names: A Artemeva, A. Artemeva, A. V. Artemyeva, A. V. Artem’eva, A.V. Artemeva, A.V. Artemyeva, Antonina V. Artem’eva, Artemeva, Antonina V., А. В. Артемьева
Institution: BIOCAD (Russia)
ORCID: 0000-0002-5306-3377
Observed ORCID: 0000-0002-5306-3377
OpenAlex ID: A5026365582
Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial
2021 · Luís Puig, Andrey L. Bakulev, et al. · Dermatology and Therapy · 47
PDF
Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis
2019 · A. A. Kubanov, A. L. Bakulev, et al. · Vestnik dermatologii i venerologii · 25
PDF
Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext
2019 · A. L. Bakulev, A. V. Samtsov, et al. · Vestnik dermatologii i venerologii · 18
PDF
Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis
2017 · A. V. Samtsov, V. R. Khairutdinov, et al. · Vestnik dermatologii i venerologii · 16
PDF
Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
2024 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 13
PDF
Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2
2023 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 13
The Efficacy and Safety of Rituximab Biosimilar (acellbia®) in Rheumatoid Arthritis as the First Biological Agent: Results of Phase Iii (alterra) Clinical Trial
2017 · E. L. Nasonov, V. I. Mazurov, et al. · Rheumatology Science and Practice · 13
Association of insulinase gene polymorphisms with type 2 diabetes mellitus in patients from the Moscow population
2009 · P. A. Slominsky, O. V. Pivovarova, et al. · Russian Journal of Genetics · 9
Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial
2022 · Alexey V. Samtsov, Andrey L. Bakulev, et al. · PLoS ONE · 8
PDF
Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial
2021 · Luis Puig, Andrey L. Bakulev, et al. · Vestnik dermatologii i venerologii · 7
PDF
Efficacy and safety profile of 2-year netakimab treatment in patients with moderate-to-severe plaque psoriasis in terms of the randomized double-blind placebo-controlled BCD-085-7/PLANETA clinical trial
2022 · Andrey I. Bakulev, Alexey V. Samtsov, et al. · Vestnik dermatologii i venerologii · 6
PDF
Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
2018 · Т. V. Korotaeva, A. V. Samtsov, et al. · Modern Rheumatology Journal · 5
PDF
Результаты терапии больных бляшечным псориазом с псориатической ониходистрофией препаратом BCD-085. Анализ II фазы клинического исследования
2019 · А. В. Артемьева, Е. В. Черняева, et al. · Экспериментальная и клиническая фармакология · 2
FRI0208 Comparison of efficacy, safety and pharmacokinetics of infliximab biosimilar (BCD-055) and innovator infliximab
2017 · L Denisov, I Gordeev, et al. · Annals of the Rheumatic Diseases · 2
PDF
SAT0206 Results of the alterra clinical trial – the efficacy of the alternative dosing regimen for rituximab biosimilar in bdmards naive patients with rheumatoid arthritis
2018 · V. Mazurov, L. Denisov, et al. · Annals of the Rheumatic Diseases · 1
PDF
Efficacy and Safety of Netakimab in Children and Adolescents with Moderate-to-Severe Plaque Psoriasis: Results of the Core Treatment Period (12 Weeks) of the Randomized Placebo-Controlled Phase III Clinical Trial BCD-085-16/PLANETA-KIDS
2026 · Nikolay N. Murashkin, Andrey L. Bakulev, et al. · Вопросы современной педиатрии
PDF
Works count: 17
Citation count: 185
H-index: 8
I10-index: 7
Year
Topic
Type